Sporos Bioventures

Sporos Bioventures is a private biopharmaceutical company that aims to transform the drug development process by focusing on key mechanisms and targets of disease to accelerate drug discovery research to early clinical stage assets using a centralized infrastructure. Programs are discovered and developed by Sporos portfolio companies or by the internal Sporos biodiscovery group, which focuses on small molecules and antibody therapeutics. The Company identifies novel disease mechanisms and strategically deploys people, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos’ current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. Sporos provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. Sporos is headquartered in Houston and has offices in New York and Boston. Sporos Bioventures owns equity interests in several biopharma entities including Tvardi Therapeutics, Asylia Therapeutics, and Sporos BioDiscovery.